Last updated: 5 September 2024 at 4:12pm EST

Catriona Yale Net Worth




The estimated Net Worth of Catriona Yale is at least $7.03 Millón dollars as of 3 September 2024. Catriona Yale owns over 949 units of Akero Therapeutics Inc stock worth over $1,969,666 and over the last 5 years Catriona sold AKRO stock worth over $5,056,775.

Catriona Yale AKRO stock SEC Form 4 insiders trading

Catriona has made over 19 trades of the Akero Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Catriona exercised 949 units of AKRO stock worth $588 on 3 September 2024.

The largest trade Catriona's ever made was selling 40,000 units of Akero Therapeutics Inc stock on 13 September 2022 worth over $1,099,200. On average, Catriona trades about 6,789 units every 41 days since 2019. As of 3 September 2024 Catriona still owns at least 76,880 units of Akero Therapeutics Inc stock.

You can see the complete history of Catriona Yale stock trades at the bottom of the page.



What's Catriona Yale's mailing address?

Catriona's mailing address filed with the SEC is 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Akero Therapeutics Inc

Over the last 5 years, insiders at Akero Therapeutics Inc have traded over $146,260,704 worth of Akero Therapeutics Inc stock and bought 4,870,000 units worth $104,250,550 . The most active insiders traders include Group, Llc Green Jeremy Red..., Trust Blue Horizon Enterpri... y G. Walmsley Graham. On average, Akero Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,642,344. The most recent stock trade was executed by Jonathan Young on 3 September 2024, trading 5,000 units of AKRO stock currently worth $133,600.



What does Akero Therapeutics Inc do?

akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.



What does Akero Therapeutics Inc's logo look like?

Akero Therapeutics Inc logo

Complete history of Catriona Yale stock trades at Akero Therapeutics Inc

Fecha
#
Empresa
Persona
Trans.
Transacción
Acciones Precio por acción Precio total Acciones después de Fuente
3 Sep 2024 Catriona Yale
Chief Development Officer
Uso de opción 949 $0.62 $588
3 Sep 2024
76,880
23 Aug 2024 Catriona Yale
Chief Development Officer
Uso de opción 14,051 $0.62 $8,712
23 Aug 2024
81,131
11 Jun 2024 Catriona Yale
Chief Development Officer
Venta 2,825 $22.64 $63,958
11 Jun 2024
74,867
13 Mar 2024 Catriona Yale
Chief Development Officer
Venta 723 $28.33 $20,483
13 Mar 2024
77,692
4 Mar 2024 Catriona Yale
Chief Development Officer
Uso de opción 20,646 $13.96 $288,218
4 Mar 2024
99,061
14 Dec 2023 Catriona Yale
Chief Development Officer
Venta 597 $20.76 $12,394
14 Dec 2023
77,910
13 Sep 2023 Catriona Yale
Chief Development Officer
Venta 5,617 $48.32 $271,413
13 Sep 2023
46,010
28 Aug 2023 Catriona Yale
Chief Development Officer
Uso de opción 5,745 $6.36 $36,538
28 Aug 2023
52,372
21 Jun 2023 Catriona Yale
Chief Development Officer
Venta 33,349 $51.74 $1,725,477
21 Jun 2023
46,627
13 Jun 2023 Catriona Yale
Chief Development Officer
Venta 591 $55.16 $32,600
13 Jun 2023
79,976
13 Jan 2023 Catriona Yale
Chief Development Officer
Venta 5,000 $50.53 $252,650
13 Jan 2023
81,268
9 Dec 2022 Catriona Yale
Chief Development Officer
Venta 5,000 $43.23 $216,150
9 Dec 2022
86,268
10 Nov 2022 Catriona Yale
Chief Development Officer
Venta 5,000 $39.42 $197,100
10 Nov 2022
72,073
10 Oct 2022 Catriona Yale
Chief Development Officer
Venta 5,000 $37.99 $189,950
10 Oct 2022
77,073
13 Sep 2022 Catriona Yale
Chief Development Officer
Venta 40,000 $27.48 $1,099,200
13 Sep 2022
82,073
15 Oct 2021 Catriona Yale
Chief Development Officer
Venta 12,500 $21.59 $269,875
15 Oct 2021
120,921
15 Sep 2021 Catriona Yale
Chief Development Officer
Venta 12,500 $24.69 $308,625
15 Sep 2021
133,421
16 Aug 2021 Catriona Yale
Chief Development Officer
Venta 10,000 $18.79 $187,900
16 Aug 2021
145,921
15 Jul 2021 Catriona Yale
Chief Development Officer
Venta 10,000 $20.90 $209,000
15 Jul 2021
155,921


Akero Therapeutics Inc executives and stock owners

Akero Therapeutics Inc executives and other stock owners filed with the SEC include: